Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers

Journal of Immunological Methods

Volumn 340, Issue 1, 2009, Pages 11-24

  Lissina, Anna ^a   Ladell, Kristin ^a   Skowera, Ania ^b,c   Clement, Matthew ^a   Edwards, Emily ^a   Seggewiss, Ruth ^d   van den Berg, Hugo A ^e   Gostick, Emma ^a   Gallagher, Kathleen ^a   Jones, Emma ^a   Melenhorst, J Joseph ^f   Godkin, Andrew J ^a   Peakman, Mark ^b,c   Price, David A ^a   Sewell, Andrew K ^a   Wooldridge, Linda ^a  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e UNIVERSITY OF WARWICK   (United Kingdom)

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Autoimmunity; Cancer immunology; Low avidity CTL; T cell; Tetramer

Indexed keywords

DASATINIB; T LYMPHOCYTE RECEPTOR; TETRAMER;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAINING;

ADULT; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HLA-DR ANTIGENS; HUMANS; MICE; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STAINING AND LABELING; THIAZOLES;

MURINAE;

EID: 57249095832     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2008.09.014     Document Type: Article

References (34)

1. Altman J.D., Moss P.A., Goulder P.J., Barouch D.H., McHeyzer-Williams M.G., Bell J.I., McMichael A.J., and Davis M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science 274 (1996) 94
2. Antonescu C.R., Busam K.J., Francone T.D., Wong G.C., Guo T., Agaram N.P., Besmer P., Jungbluth A., Gimbel M., Chen C.T., Veach D., Clarkson B.D., Paty P.B., and Weiser M.R. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int. J. Cancer 121 (2007) 257
3. Arif S., Tree T.I., Astill T.P., Tremble J.M., Bishop A.J., Dayan C.M., Roep B.O., and Peakman M. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113 (2004) 451
4. Burrows S.R., Kienzle N., Winterhalter A., Bharadwaj M., Altman J.D., and Brooks A. Peptide-MHC class I tetrameric complexes display exquisite ligand specificity. J. Immunol. 165 (2000) 6229
5. Carter T.A., Wodicka L.M., Shah N.P., Velasco A.M., Fabian M.A., Treiber D.K., Milanov Z.V., Atteridge C.E., Biggs III W.H., Edeen P.T., Floyd M., Ford J.M., Grotzfeld R.M., Herrgard S., Insko D.E., Mehta S.A., Patel H.K., Pao W., Sawyers C.L., Varmus H., Zarrinkar P.P., and Lockhart D.J. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. 102 (2005) 11011
6. Cebecauer M., Guillaume P., Hozak P., Mark S., Everett H., Schneider P., and Luescher I.F. Soluble MHC-peptide complexes induce rapid death of CD8+ CTL. J. Immunol. 174 (2005) 6809
7. Chang L., Kjer-Nielsen L., Flynn S., Brooks A.G., Mannering S.I., Honeyman M.C., Harrison L.C., McCluskey J., and Purcell A.W. Novel strategy for identification of candidate cytotoxic T-cell epitopes from human preproinsulin. Tissue Antigens 62 (2003) 408
8. Chattopadhyay P.K., Price D.A., Harper T.F., Betts M.R., Yu J., Gostick E., Perfetto S.P., Goepfert P., Koup R.A., De Rosa S.C., Bruchez M.P., and Roederer M. Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat. Med. 12 (2006) 972
9. Cole D.K., Pumphrey N.J., Boulter J.M., Sami M., Bell J.I., Gostick E., Price D.A., Gao G.F., Sewell A.K., and Jakobsen B.K. Human TCR-binding affinity is governed by MHC class restriction. J. Immunol. 178 (2007) 5727
10. D'Oro U., Vacchio M.S., Weissman A.M., and Ashwell J.D. Activation of the Lck tyrosine kinase targets cell surface T cell antigen receptors for lysosomal degradation. Immunity 7 (1997) 619
11. Dietrich J., Menne C., Lauritsen J.P., von Essen M., Rasmussen A.B., Odum N., and Geisler C. Ligand-induced TCR down-regulation is not dependent on constitutive TCR cycling. J. Immunol. 168 (2002) 5434
12. Guillaume P., Legler D.F., Boucheron N., Doucey M.A., Cerottini J.C., and Luescher I.F. Soluble Major Histocompatibility complex-peptide octamers with impaired CD8 binding selectively induce fas-dependent apoptosis. J. Biol. Chem. 278 (2003) 4500
13. Hutchinson S.L., Wooldridge L., Tafuro S., Laugel B., Glick M., Boulter J.M., Jakobsen B.K., Price D.A., and Sewell A.K. The CD8 T cell coreceptor exhibits disproportionate biological activity at extremely low binding affinities. J. Biol. Chem. 278 (2003) 24285
14. Krangel M.S. Endocytosis and recycling of the T3-T cell receptor complex. The role of T3 phosphorylation. J. Exp. Med. 165 (1987) 1141
15. Laugel B., Boulter J.M., Lissin N., Vuidepot A., Li Y., Gostick E., Crotty L.E., Douek D.C., Hemelaar J., Price D.A., Jakobsen B.K., and Sewell A.K. Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition. J. Biol. Chem. 280 (2005) 1882
16. Laugel B., van den Berg H.A., Gostick E., Cole D.K., Wooldridge L., Boulter J.M., Milicic A., Price D.A., and Sewell A.K. Different T cell receptor affinity thresholds and CD8 coreceptor dependency govern cytotoxic T lymphocyte activation and tetramer binding properties. J. Biol. Chem. 282 (2007) 23799
17. Lombardo L.J., Lee F.Y., Chen P., Norris D., Barrish J.C., Behnia K., Castaneda S., Cornelius L.A., Das J., Doweyko A.M., Fairchild C., Hunt J.T., Inigo I., Johnston K., Kamath A., Kan D., Klei H., Marathe P., Pang S., Peterson R., Pitt S., Schieven G.L., Schmidt R.J., Tokarski J., Wen M.L., Wityak J., and Borzilleri R.M. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47 (2004) 6658
18. Luton F., Buferne M., Davoust J., Schmitt-Verhulst A.M., and Boyer C. Evidence for protein tyrosine kinase involvement in ligand-induced TCR/CD3 internalization and surface redistribution. J. Immunol. 153 (1994) 63
19. Magnusson M.K., Meade K.E., Nakamura R., Barrett J., and Dunbar C.E. Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene. Blood 100 (2002) 1088
20. Mamalaki C., Elliott J., Norton T., Yannoutsos N., Townsend A.R., Chandler P., Simpson E., and Kioussis D. Positive and negative selection in transgenic mice expressing a T-cell receptor specific for influenza nucleoprotein and endogenous superantigen. Develop. Immunol. 3 (1993) 159
21. Melenhorst J.J., Scheinberg P., Chattopadhyay P.K., Lissina A., Gostick E., Cole D.K., Wooldridge L., van den Berg H.A., Bornstein E., Hensel N.F., Douek D.C., Roederer M., Sewell A.K., Barret A.J., and Price D.A. Dectection of low avidity CD8(+) T cell populations with coreceptor-enhanced peptide-major histocompatibility complex class I tetramers. J. Immunol. Methods 338 (2008) 31
22. Minami Y., Samelson L.E., and Klausner R.D. Internalization and cycling of the T cell antigen receptor. Role of protein kinase C. J. Biol. Chem. 262 (1987) 13342
23. Niedergang F., Dautry-Varsat A., and Alcover A. Peptide antigen or superantigen-induced down-regulation of TCRs involves both stimulated and unstimulated receptors. J. Immunol. 159 (1997) 1703
24. Purbhoo M.A., Boulter J.M., Price D.A., Vuidepot A.L., Hourigan C.S., Dunbar P.R., Olson K., Dawson S.J., Phillips R.E., Jakobsen B.K., Bell J.I., and Sewell A.K. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J. Biol. Chem. 276 (2001) 32786
25. San Jose E., Borroto A., Niedergang F., Alcover A., and Alarcon B. Triggering the TCR complex causes the downregulation of nonengaged receptors by a signal transduction-dependent mechanism. Immunity 12 (2000) 161
26. Schittenhelm M.M., Shiragar S., Schroeder A., Corbin A.S., Griffith D., Lee F.Y., Bokemeyer C., Deininger M.W.N., Drucker B.J., and Heinrich M.C. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. 66 (2006) 473
27. Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., and Sawyers C.L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305 (2004) 399
28. Skowera A., Ellis R.J., Varela-Calvino R., Arif S., Huang G.C., Van-Krinks C., Zaremba A., Rackham C., Allen J.S., Tree T.I., Zhao M., Dayan C.M., Sewell A.K., Unger W., Drijfhout J.W., Ossendorp F., Roep B.O., and Peakman M. CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope. J. Clin. Invest. 118 (2008) 3390
29. van den Berg H.A., Wooldridge L., Laugel B., and Sewell A.K. Coreceptor CD8-driven modulation of T cell antigen receptor specificity. J. Theor. Biol. 249 (2007) 395
30. Weichsel R., Dix C., Wooldridge L., Clement M., Fenton-May A., Sewell A.K., Zezula J., Greiner E., Gostick E., Price D.A., Einsele H., and Seggewiss R. Profound inhibition of antigen-specific T-cell effector functions by dasatinib. Clin. Cancer Res. 14 (2008) 2484
31. Whelan J.A., Dunbar P.R., Price D.A., Purbhoo M.A., Lechner F., Ogg G.S., Griffiths G., Phillips R.E., Cerundolo V., and Sewell A.K. Specificity of CTL interactions with peptide-MHC class I tetrameric complexes is temperature dependent. J. Immunol. 163 (1999) 4342
32. Wooldridge L., van den Berg H.A., Glick M., Gostick E., Laugel B., Hutchinson S.L., Milicic A., Brenchley J.M., Douek D.C., Price D.A., and Sewell A.K. Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor- antigen complexes at the cell surface. J. Biol. Chem. 280 (2005) 27491
33. Wooldridge, L., Lissina, L., Cole, D.K., van den Berg, H.A., Price, D.A., Sewell, A.K., in press. Tricks with tetramers: how to get the most from multimeric peptide-MHC. Immunology.
34. Xu X.N., Purbhoo M.A., Chen N., Mongkolsapaya J., Cox J.H., Meier U.C., Tafuro S., Dunbar P.R., Sewell A.K., Hourigan C.S., Appay V., Cerundolo V., Burrows S.R., McMichael A.J., and Screaton G.R. A novel approach to antigen-specific deletion of CTL with minimal cellular activation using alpha3 domain mutants of MHC class I/peptide complex. Immunity 14 (2001) 591